← FDA DRUG APPROVALS

FDA ANDA · ANDA207808

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

Sponsor: RHODES PHARMS

APPLICATION
ANDA207808
TYPE
ANDA
ORIGINAL APPROVAL
2018-03-30
LATEST ACTION
2026-06-18
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

HYDROCODONE BITARTRATE AND ACETAMINOPHENDiscontinued
ACETAMINOPHEN 300MG, HYDROCODONE BITARTRATE 10MG · TABLET · ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHENDiscontinued
ACETAMINOPHEN 300MG, HYDROCODONE BITARTRATE 5MG · TABLET · ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHENDiscontinued
ACETAMINOPHEN 300MG, HYDROCODONE BITARTRATE 7.5MG · TABLET · ORAL

Approval history

2026-06-18REMS · Supplement 12AP
2025-12-22Labeling · Supplement 11 · standardAP
2025-02-11Labeling · Supplement 8 · standardAP
2023-12-15Labeling · Supplement 7 · standardAP
2021-03-04Labeling · Supplement 5 · standardAP
2019-10-11Labeling · Supplement 3 · standardAP
2018-09-18REMS · Supplement 1AP
2018-03-30UNKNOWN · Original · standard — REMS ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →